Nirsevimab can decrease hospitalizations by 83.21% in babies more youthful than 12 months with breathing syncytial infection (RSV)- related lower breathing system infection (LRTI), according to a news release published by Sanofi-Aventis Groupe.
The Hospitalized RSV Monoclonal Antibody Avoidance (HARMONIE) stage 3b trial (ClinicalTrials.gov Identifier: NCT05437510) is a big interventional scientific trial to identify the security and effectiveness of a single intramuscular dosage of nirsevimab. Real-world information were gathered from more than 8000 babies throughout 250 treatment websites in Germany and the UK throughout the 2022 to 2023 RSV season.
Compared to babies who got no RSV intervention, scientists observed that 1 dosage of nirsevimab resulted in decreases in a number of steps, as follows:
- Hospitalizations due to RSV-related LRTI (83.21%; 95% CI, 67.77-92.04; P <